# EDGAR Filing Document

**Accession Number:** 0001990446
**File Stem:** 0001683168-25-007611
**Filing Date:** 2025-10
**Character Count:** 87870
**Document Hash:** 8da96bf0d9cf812de233dae56ff78c7c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001683168-25-007611.hdr.sgml**: 20251016

**ACCESSION NUMBER**: 0001683168-25-007611

**CONFORMED SUBMISSION TYPE**: 10-Q/A

**PUBLIC DOCUMENT COUNT**: 56

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20251016

**DATE AS OF CHANGE**: 20251016

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Trans American Aquaculture, Inc
- **CENTRAL INDEX KEY:** 0001990446
- **STANDARD INDUSTRIAL CLASSIFICATION:** AGRICULTURE PRODUCTION - LIVESTOCK & ANIMAL SPECIALTIES [0200]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 020685828
- **STATE OF INCORPORATION:** CO
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-56640
- **FILM NUMBER:** 251398323

**BUSINESS ADDRESS:**
- **STREET 1:** 1022 SHADYSIDE LANE
- **CITY:** DALLAS
- **STATE:** TX
- **ZIP:** 75223
- **BUSINESS PHONE:** 972-358-6037

**MAIL ADDRESS:**
- **STREET 1:** 1022 SHADYSIDE LANE
- **CITY:** DALLAS
- **STATE:** TX
- **ZIP:** 75223

?xml version='1.0' encoding='ASCII'? TRANS AMERICAN AQUACULTURE, INC. 10-Q

[**Table of Contents**](#q2_001)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**FORM 10-Q/A**

Amendment 1

(Mark One)

---

| | |
|:---|:---|
| ☒ | **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |
|  | For the quarterly period ended **June 30, 2025** |

---

Or

---

| | |
|:---|:---|
| ☐ | **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934** |
|  | For the transition period from ________________ to ________________ |

---

Commission File Number: **000-56640**

**TRANS AMERICAN AQUACULTURE, INC.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Colorado** | **02-0685828** |
| (State of other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
| **1022 Shadyside Lane, Dallas, TX** | **75223** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

**<u>(972) 358-6037</u>**

(Registrant's telephone number, including area code)

Securities registered pursuant to section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Not applicable | Not applicable | Not applicable |

---

Securities registered pursuant to Section 12(g) of the Act: **Common Stock, par value $0.000001**

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares of the registrant's common stock, $0.000001 par value per share, outstanding as of October 9, 2025, was 1,805,926,955.

**EXPLANATORY NOTE**

This Amendment No. 1 to the Quarterly Report on Form 10-Q is being filed 1) to revise the Balance Sheet and Consolidated Statements of Stockholders' Equity to reconcile the common stock issued value to the appropriate prior quarter and a minor adjustment to a preferred stock to be issued line item as a result of a reclassification, and 2) to furnish the Interactive Data files as Exhibit 101, in accordance with Rule 405 of Regulation S-T. No other changes have been made to the Form 10-Q/A, as originally filed on October 15, 2025.

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| [PART I—FINANCIAL INFORMATION](#q2_002) | 4 |
| [Item 1. Financial Statements](#q2_003) | 4 |
| [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](#q2_004) | 19 |
| [Item 3. Quantitative and Qualitative Disclosures About Market Risk](#q2_005) | 24 |
| [Item 4. Controls and Procedures](#q2_006) | 24 |
| [PART II—OTHER INFORMATION](#q2_007) | 25 |
| [Item 1. Legal Proceedings.](#q2_008) | 25 |
| [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.](#q2_009) | 25 |
| [Item 5. Other Information.](#q2_010) | 25 |
| [Item 6. Exhibits](#q2_011) | 26 |
| [SIGNATURES](#q2_012) | 27 |

---

**PART I—FINANCIAL INFORMATION**

**Item 1. Financial Statements**

Trans American Aquaculture, Inc.

(Formerly Gold River Productions, Inc.)

Consolidated Balance Sheets

---

| | | |
|:---|:---|:---|
|  | Unaudited<br>June 30,<br>2025 |<br>December 31,<br>2024 |
| ASSETS |  |  |
| CURRENT ASSETS |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $198 | $– |
| &nbsp;&nbsp;&nbsp;Other receivable |  | 26480 |
| &nbsp;&nbsp;&nbsp;Inventory | 302409 | 230830 |
| &nbsp;&nbsp;&nbsp;Other Asset | 716 | – |
| TOTAL CURRENT ASSETS | 303323 | 257310 |
| PROPERTY AND EQUIPMENT | 1237992 | 1237992 |
| &nbsp;&nbsp;&nbsp;Less accumulated depreciation | (460812) | (547287) |
| NET PROPERTY AND EQUIPMENT | 777180 | 690705 |
| TOTAL ASSETS | $1080503 | $948015 |
| LIABILITIES AND STOCKHOLDERS' EQUITY |  |  |
| CURRENT LIABILITIES |  |  |
| &nbsp;&nbsp;&nbsp;Bank overdraft | $– | $1000 |
| &nbsp;&nbsp;&nbsp;Accounts payable | 751883 | 530776 |
| &nbsp;&nbsp;&nbsp;Accrued interest expense | 850388 | 114568 |
| &nbsp;&nbsp;&nbsp;Other accrued expenses | 918693 | 753870 |
| &nbsp;&nbsp;&nbsp;Income tax payable |  |  |
| &nbsp;&nbsp;&nbsp;Related parties notes | 1459343 | 1646636 |
| &nbsp;&nbsp;&nbsp;Current portion of notes payable | 673722 | 562063 |
| TOTAL CURRENT LIABILITIES | 4654029 | 3608912 |
| LONG-TERM LIABILITIES |  |  |
| &nbsp;&nbsp;&nbsp;Notes payable, net of current portion | 145680 | 561087 |
| &nbsp;&nbsp;&nbsp;Deferred tax liability, net | – | – |
| TOTAL LONG-TERM LIABILITIES | 145680 | 561087 |
| STOCKHOLDERS' (DEFICIT) EQUITY |  |  |
| &nbsp;&nbsp;&nbsp;Common stock, $.000001 par value, 6,000,000,000 shares authorized, 1,805,926,955 and 1,805,926,955 shares issued and outstanding |  |  |
| &nbsp;&nbsp;&nbsp;Preferred Stock, Series A, .000001 par value 9,078,000 and 9,078,000 shares authorized, 9,078,000 issued and outstanding |  |  |
| &nbsp;&nbsp;&nbsp;Preferred Stock, Series B, .000001 par value 5,000 and 5,000 shares authorized, 5,000 issued and outstanding |  |  |
| &nbsp;&nbsp;&nbsp;Preferred Stock, Series C, $.000001 par value, 100,000 and 100,000 shares authorized, 100,000 issued and outstanding |  |  |
| &nbsp;&nbsp;&nbsp;Preferred Stock, Series C to be issued | (283967) |  |
| &nbsp;&nbsp;&nbsp;Preferred Stock, Series D, .000001 par value, 1,295 shares authorized, 1,149 and 1,149 issued and outstanding |  |  |
| &nbsp;&nbsp;&nbsp;Additional paid in capital - common stock | 121118 | 99980 |
| &nbsp;&nbsp;&nbsp;Additional paid in capital - preferred stock (Series C) | 1287091 | 1317467 |
| &nbsp;&nbsp;&nbsp;Additional paid in capital - preferred stock (Series D) | 1149863 | 1036135 |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (5993312) | (5675567) |
| TOTAL STOCKHOLDERS' (DEFICIT) EQUITY | (3719207) | (3221985) |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $1080503 | $948014 |

---

The accompanying notes are an integral part of these financial statements.

Trans American Aquaculture, Inc.

(Formerly Gold River Productions, Inc.)

Consolidated Statements of Operations

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | For the three months ended | For the three months ended | For the six months ended | For the six months ended |
|  | June 30, | June 30, | June 30, | June 30, |
|  | 2025 | 2024 | 2025 | 2024 |
| REVENUES |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Sales and service | $– | $5019 | $– | $315145 |
| COST OF REVENUES |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Cost of revenues | – | 1771 | – | 223299 |
| GROSS MARGIN |  | 3248 |  | 91846 |
| GENERAL AND ADMINISTRATIVE EXPENSES | 108290 | 126993 | 182961 | 321383 |
| OTHER INCOME (EXPENSE) |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Other income | 918 |  | 918 | 700 |
| &nbsp;&nbsp;&nbsp;Other expense | (8420) | (65328) | (8420) | (65974) |
| &nbsp;&nbsp;&nbsp;Interest expense | (88246) | (141238) | (127282) | (273520) |
| TOTAL OTHER INCOME (EXPENSE) | (95748) | (206566) | (134784) | (338795) |
| NET INCOME (LOSS) BEFORE TAXES | (204038) | (330311) | (317745) | (568332) |
| INCOME TAX (EXPENSE) BENEFIT | – | – | – | – |
| NET INCOME (LOSS) | $(204038) | $(330311) | $(317745) | $(568332) |
| Basic and Diluted Net loss per common share | $(0.000113) | $(0.000210) | $(0.000176) | $(0.000211) |
| Weighted average common shares outstanding - basic | 1805926955 | 1464250830 | 1805926955 | 1460261010 |

---

The accompanying notes are an integral part of these financial statements.

Trans American Aquaculture, Inc.

(Formerly Gold River Productions, Inc.)

Consolidated Statements of Stockholders' Equity

For the six months ended June 30, 2024 and 2025

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | | Common Stock | Common Stock | Preferred Stock, Series A | Preferred Stock, Series A | Preferred Stock, Series B | Preferred Stock, Series B |
|  | Members'<br>Capital | Shares | Amount | Shares | Amount | Shares | Amount |
| Balance December 31, 2023 | $– | 1452655528 | $100000 | 9078000 | $– | 5000 | $– |
| &nbsp;&nbsp;Issuance of common shares |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Issuance of preferred shares |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Stock Dividends |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Net loss | – | – | – | – | – | – | – |
| Balance March 31, 2024 | $– | 1452655528 | $100000 | 9078000 | $– | 5000 | $– |
| &nbsp;&nbsp;Issuance of common shares |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Issuance of preferred shares |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Stock Dividends |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Net loss | – | – | – | – | – | – | – |
| Balance June 30, 2024 | $– | 1452655528 | $100000 | 9078000 | $– | 5000 | $– |
| Balance December 31, 2024 | $– | 1805926955 | $121118 | 9078000 | $– | 5000 | $– |
| &nbsp;&nbsp;Issuance of common shares |  | 7615277 | 21118 |  |  |  |  |
| &nbsp;&nbsp;Issuance of preferred shares |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Stock Dividends |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Net loss | – | – | – | – | – | – | – |
| Balance March 31, 2025 | $– | 1805926955 | $121118 | 9078000 | $– | 5000 | $– |
| &nbsp;&nbsp;Issuance of common shares |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Issuance of preferred shares |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Stock Dividends |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Net loss | – | – | – | – | – | – | – |
| Balance June 30, 2025 | $– | 1805926955 | $121118 | 9078000 | $– | 5000 | $– |

---

Trans American Aquaculture, Inc.

(Formerly Gold River Productions, Inc.)

Consolidated Statements of Stockholders' Equity (Continued)

For the six months ended June 30, 2024 and 2025

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | Preferred Stock, Series C | Preferred Stock, Series C | Preferred Stock, Series D | Preferred Stock, Series D | Shares to be issued | Shares to be issued | | |
|  | Shares | Amount | Shares | Amount | Shares | Amount | Accumulated<br>Deficit |<br>Total |
| Balance December 31, 2023 | 100000 | $1287091 | 1076 | $1076863 |  | $– | $(2943231) | $(479277) |
| &nbsp;&nbsp;Issuance of common shares |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Issuance of preferred shares |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Stock Dividends |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Net loss | – | – | – | – |  | – | (238021) | (238021) |
| Balance March 31, 2024 | 100000 | $1287091 | 1076 | $1076863 |  | $– | $(3181252) | $(717298) |
| &nbsp;&nbsp;Issuance of common shares |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Issuance of preferred shares |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Stock Dividends |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Net loss | – | – | – | – |  | – | (330311) | (330311) |
| Balance June 30, 2024 | 100000 | $1287091 | 1076 | $1076863 |  | $– | (3511563) | $(1047609) |
| Balance December 31, 2024 | 100000 | $1287091 | 1076 | $1076863 |  | $– | $(5675567) | $(3221985) |
| &nbsp;&nbsp;Issuance of common shares |  |  |  |  |  |  |  | 21118 |
| &nbsp;&nbsp;Issuance of preferred shares |  |  | 30 | 33000 |  |  |  | 33000 |
| &nbsp;&nbsp;Stock Dividends |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Net loss | – | – | – | – |  | – | (113707) | (113707) |
| Balance March 31, 2025 | 100000 | $1287091 | 1106 | $1109863 |  | $– | $(5789274) | $(3281574) |
| &nbsp;&nbsp;Issuance of common shares |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Issuance of preferred shares |  |  | 43 | 40000 |  | (283967) |  | (233595) |
| &nbsp;&nbsp;Stock Dividends |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Net loss | – | – | – | – |  | – | (204038) | (204038) |
| Balance June 30, 2025 | 100000 | $1287091 | 1149 | $1149863 |  | $(283967) | $(5993312) | $(3719207) |

---

The accompanying notes are an integral part of these financial statements.

Trans American Aquaculture, Inc.

(Formerly Gold River Productions, Inc.)

Consolidated Statements of Cash Flows

---

| | | |
|:---|:---|:---|
|  | Unaudited | Unaudited |
|  | For the six months ending | For the six months ending |
|  | June 30, | June 30, |
|  | 2025 | 2024 |
| CASH FLOWS FROM OPERATING ACTIVITIES: |  |  |
| Net loss | $(317745) | $(568332) |
| Noncash items included in net loss: |  |  |
| &nbsp;&nbsp;&nbsp;Depreciation expense | 4865 | 35246 |
| &nbsp;&nbsp;&nbsp;Common stock issued for professional services |  | 19012 |
| (Increase) decrease in: |  |  |
| &nbsp;&nbsp;&nbsp;Other receivable | 12794 | (30526) |
| &nbsp;&nbsp;&nbsp;Inventory | (74057) | (122838) |
| &nbsp;&nbsp;&nbsp;Deferred taxes |  |  |
| &nbsp;&nbsp;&nbsp;Other assets |  | (904) |
| Increase (decrease) in: |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable and other accrued expenses | (989069) | 62359 |
| &nbsp;&nbsp;&nbsp;Income tax payable |  |  |
| &nbsp;&nbsp;&nbsp;Accrued interest expense | 646403 | 216203 |
| CASH USED IN OPERATING ACTIVITIES | (716807) | (389780) |
| CASH FLOWS FROM INVESTING ACTIVITIES: |  |  |
| &nbsp;&nbsp;&nbsp;Cash paid for the purchase of fixed assets |  | (12216) |
| &nbsp;&nbsp;&nbsp;Accumulated Depreciation | 10616 | – |
| CASH USED IN INVESTING ACTIVITIES | 10616 | (12216) |
| CASH FLOWS FROM FINANCING ACTIVITIES: |  |  |
| &nbsp;&nbsp;&nbsp;Payment of bank overdraft | (1000) |  |
| &nbsp;&nbsp;&nbsp;Bank overdraft |  | 7976 |
| &nbsp;&nbsp;&nbsp;Proceeds from shareholder notes payable |  | 31649 |
| &nbsp;&nbsp;&nbsp;Payments on shareholder notes payable | (216) | (70850) |
| &nbsp;&nbsp;&nbsp;Payments on notes payable |  | (32505) |
| &nbsp;&nbsp;&nbsp;Proceeds from on related party notes payable | 627912 | 443000 |
| &nbsp;&nbsp;&nbsp;Payments due to related parties |  | (16127) |
| &nbsp;&nbsp;&nbsp;Contributions |  |  |
| &nbsp;&nbsp;&nbsp;Stock Dividends |  |  |
| &nbsp;&nbsp;&nbsp;Issuance of Preferred Shares | 73000 | – |
| CASH PROVIDED BY FINANCING ACTIVITIES | 699696 | 395397 |
| NET INCREASE (DECREASE) | (6497) | (6600) |
| CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD | 6694 | 6600 |
| CASH AND CASH EQUIVALENTS AT END OF PERIOD | $197 | $0 |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: |  |  |
| &nbsp;&nbsp;&nbsp;Cash paid for interest | $– | $57318 |
| &nbsp;&nbsp;&nbsp;Cash paid for income taxes | $– | $– |
| NON-CASH |  |  |
| &nbsp;&nbsp;&nbsp;Preferred series D stock dividends | $– | $43995 |
| &nbsp;&nbsp;&nbsp;Common stock issued for services rendered | $– | $19012 |
| &nbsp;&nbsp;&nbsp;Capitalization of related party member notes to members' capital | $– | $– |

---

The accompanying notes are an integral part of these financial statements.

Trans American Aquaculture, Inc.

(Formerly Gold River Productions, Inc.)

Notes to Consolidated Financial Statements

June 30, 2025 and 2025

NOTE 1 – BUSINESS ORGANIZATION

Business Organization

Trans American Aquaculture, Inc. formerly Gold River Productions, Inc. (GRP), ("the Company") was incorporated in the State of Delaware on September 18, 2006, as Polythene Metro Corp before being acquired by Gold River Productions, Inc. on January 25, 2007. The Company was re-incorporated in the State of Colorado in July 2018. In February 2023, pursuant to shareholder and Board approval, the Company changed its name to Trans American Aquaculture, Inc., reflective of its new management and operations, and applied to the Financial Industry Regulatory Authority ("FINRA") to change its ticker symbol from GRPS to TAAQ.

On August 28, 2022, Richard Goulding, executive and selling party of Gold River Productions, Inc. and Adam Thomas, purchaser, executed a Stock Purchase Agreement ("SPA"). Under the terms of the SPA, Mr. Goulding, agreed to sell to Adam Thomas, CEO of TAA, 9,078,000 shares of the Company's Series A Preferred Stock, and to retain 640,000 shares for later conversion to the Company's common stock. Each share of Series A Preferred Stock is convertible into 100 shares of the Company's common stock. In addition, Mr. Thomas agreed to purchase all the Company's outstanding shares of Series B Preferred Stock from Mr. Goulding for a cash payment of $5,000.

In further consideration for the sale of the shares of Series A and Series B Preferred Stock, Mr. Goulding agreed to:

1. Increase the authorized shares of the Company's common stock to three billion (3,000,000,000) shares;

2. Convert his retained 640,000 shares of Series A Preferred Stock, to 64,000,000 shares of common stock;

3. Issue to various former employees and consultants of the Company an aggregate amount of 15,248,503 shares of the Company's common stock; and

4. Complete the assignment of assets and assumption of liabilities as they existed immediately prior to the closing of the stock purchase agreement on August 29, 2022.

Following the purchase of the shares of Class A and Class B Preferred Stock, Mr. Thomas and TAA agreed to:

1. To have the Company issue shares of a Class C Preferred Stock to the former members of TAA, such shares to be convertible into 85% of the Company's common stock, but limited as to this conversion for a minimum of 12 months from the date of issuance; and

2. To cancel and withdraw the shares of Series A Preferred Stock.

On August 29, 2022, Gold River Productions, Inc. and Goulding executed an Assignment of Rights and Assumption of Liabilities Agreement whereby Gold River Productions, Inc. assigned all of its assets and liabilities to Mr. Richard Goulding (Mr. Goulding), Chairman of the Board and CEO of GRP, resulting in GRP becoming a public shell company without any assets or liabilities and became the accounting acquiree.

On September 13, 2022, Gold River Productions, Inc. and Trans American Aquaculture, LLC ("TAA") executed a Definitive Equity Exchange Agreement in a transaction accounted for as a reverse acquisition, whereby TAA became the accounting acquiror. TAA operates a large land-based shrimp farming and technology company located in South Texas. The Company produces premium quality, farm-raised white shrimp, 100% free of antibiotics and hormones, and cultivated using safe and sustainable practices. Its principal markets consist of seafood distributors, restaurants, and grocery store chains in the United States. Using decades of experience in the shrimp aquaculture industry, products are grown with our superior technology and our proprietary genetics which results in a superior fresh product always grown in the United States.

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES

Basis of Accounting

The accompanying consolidated financial statements include the accounts of Trans American Aquaculture, Inc. and its wholly owned subsidiary Trans American Aquaculture, LLC, a Texas Limited Liability Company. All significant intercompany balances and transactions have been eliminated in consolidation. The accompanying financial statements have been prepared on the accrual basis of accounting.

Cash and Cash Equivalents

For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments with an original maturity of three months or less to be cash equivalents.

Inventory

Inventory is valued at lower of cost or the net realizable value on a first-in, first-out basis. Depending on the development and growth stage of shrimp, the Company's inventory is comprised of 1) broodstock held for restocking the next harvest cycle, 2) broodstock held for sale, and shrimp held for sale. The Company evaluates realization of shrimp based on market prices at the end of each period.

Property and Equipment

Property and equipment are stated at cost. Maintenance and repairs are expensed while expenditures for renewals which prolong the lives of the assets are capitalized. When items are disposed of, the cost and accumulated depreciation are eliminated from the accounts and any net gain or loss is included in the consolidated statement of income.

For financial reporting purposes, depreciation of property and equipment is provided for by using the straight-line method based on the estimated service lives of the property as follows:

---

| | |
|:---|:---|
| Land improvements | 40 years |
| Buildings and structures | 40 years |
| Farm equipment | 10 – 20 years |
| Autos and trucks | 10 years |

---

The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If it is determined that an asset has been impaired, the amount of the impairment is charged to operations. No impairments were recognized for the periods ended June 30, 2025 and 2024.

Income Taxes

The Company uses an asset and liability approach to financial accounting and reporting for income taxes. The difference between the financial statement and tax basis of assets and liabilities is determined annually.

Deferred income tax assets and liabilities are computed for those differences that have future tax consequences using the currently enacted tax laws and rates that apply to the periods in which they are expected to affect taxable income. Valuation allowances are established, if necessary, to reduce the deferred tax asset to the amount that will more likely than not be realized. Income tax expense is the current tax payable or refundable for the period, plus or minus the net change in the deferred tax assets and liabilities.

The Company's income tax returns are subject to examination by the appropriate tax jurisdictions. As of June 30, 2025, the Company needs to file federal and state income tax returns for 2020, 2021, 2022, 2023 and 2024. During 2020, the Company had taxable income primarily as a result of a short-term capital gain of $445,500 on the sale of a joint venture interest. This resulted in taxable income of $155,200 and an unremitted federal income tax liability of $33,180. With accrued penalties and interest, the total due the IRS is approximately $58,300. All liabilities, including federal taxes, were indemnified by Goulding as part of the transaction and accordingly a receivable due from the previous owner of the Company has been recorded and netted against the tax obligation. The Company intends to file its 2020 federal tax return and pay the tax due, plus penalties in interest once it has sufficient cash to do so.

Use of Estimates

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.

Revenue Recognition

The Company recognizes revenues according to the Financial Accounting Standard Board ("FASB") Accounting Standard Codification ("ASC 606") and Accounting Standard Update ASU 2014-09 "Revenues from Contracts with Customers." Under the ASC 606, revenues is recognized when the customer obtains control of promised goods or services in amounts that reflect the consideration which the entity expected to receive in exchange of goods and service. The Company does not collect sales, value-add and other taxes collected on behalf of third parties. To determine revenue recognition, the Company performs the following five steps: (1) identify the contract with customer; (2) identify the performance obligations in contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligation in the contract; and (5) recognize revenues when (or as) the entity satisfies a performance obligation.

The Company recognizes revenue as a single performance obligation when it transfers its products to customers, being when the goods are shipped and transfers to a buyer and when performance obligation under contracted sales are completed.

Advertising and Promotion

All costs associated with advertising and promoting the Company's goods and services are expensed in the year incurred.

Concentrations of Credit Risk

The Company's financial instruments that are exposed to credit risk consist primarily of temporary cash investments and accounts receivable.

The Company maintains its cash balances at a large financial institution. At times such balances may exceed federally insured limits. The Company has not experienced any losses in an account. The Company believes it is not exposed to any significant credit risk on cash and had no balances in excess of the $250,000 FDIC limit for the period ended June 30, 2025.

For the quarter ending June 30th, 2025 and 2024, two and one customer, respectively, accounted for 100% of total revenues earned.

The Company's sole source of expected future revenue consists of the sale of a single live product which requires substantial care. Production risks such as weather, disease and other factors could affect the Company's ability to realize revenue from its inventory stock.

Subsequent Events

In preparing these consolidated financial statements, the Company has evaluated events and transactions for potential recognition or disclosure through October 14, 2025, the date the consolidated financial statements were issued.

On March 28, 2025, the Company entered into a Securities Purchase Agreement with GHS (the "March 2025 SPA") pursuant to which the Company agreed to sell GHS 114 shares of Series D.

Preferred Stock for $104,000 ($1,000 for each share of Series D Preferred Stock and ten commitment shares). At the initial closing, GHS purchased 36 shares ($1,000 per share of Series D Preferred Stock). Additional Closings will be for the purchase of Preferred Shares as follows: (a) two (2) separate purchases of fifteen (15) and fifty three (53) shares of Preferred Stock for the purchase price of $15,000 and $53,000, respectively.

In addition, pursuant to the March 2025 SPA, the Company issued to GHS warrants to purchase 306,666,667 shares of Common Stock exercisable at $0.000115 per share and terminating on March 28, 2030.

On April 2, 2025, GHS purchased 15 shares of Series D Preferred Stock under the March 2025 SPA. 40,350,887 warrants were issued to GHS.

On June 18, 2025, GHS purchased 25 shares of Series D Preferred Stock under the March 2025 SPA. 67,251,462 warrants were issued to GHS.

On July 14, 2025, GHS purchased the remaining 28 shares of Series D Preferred Stock under the March 2025 SPA. 75,321,638 warrants were issued to GHS.

On September 18, 2025, the Company entered into a Securities Purchase Agreement with GHS (the "September 2025 SPA") pursuant to which the Company agreed to sell GHS 63 shares of Series D Preferred Stock for $60,000 ($1,000 for each share of Series D Preferred Stock and ten commitment shares). At the initial closing, GHS purchased 19 shares ($1,000 per share of Series D Preferred Stock). Additional Closings will be for the purchase of Preferred Shares as follows: (a) separate purchases of 44 shares of Series D Preferred Stock for the purchase price of $44,000.

In addition, pursuant to the September 2025 SPA, the Company issued to GHS warrants to purchase 71,250,000 shares of Common Stock exercisable at $0.000345 per share and terminating on September 18, 2030.

Net Loss Per Share

Basic net loss per share is calculated by dividing the net loss available to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is calculated by using the weighted-average number of common shares outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if the dilutive potential shares of common stock had been issued. The dilutive effect of the Company is reflected in diluted net loss per share by application of the treasury stock method. The dilutive securities are excluded from the computation of diluted net loss per share when net loss is recorded for the period as their effect would be anti-dilutive.

NOTE 3 – ACCOUNTS RECEIVABLE

On December 11, 2023, the Company entered into an accounts receivable factoring agreement in the amount of $750,000. The agreement calls for 80% with recourse financing on eligible receivables. The amount received for the factored receivables on February 7, 2024, totaled $135,847, of which $0 remains outstanding after factoring fees at June 30, 2025 and $0 at June 30, 2024.

NOTE 4 – INVENTORY

The inventory at June 30, 2025, consists of shrimp broodstock held for sale, and broodstock held for restocking. Included in this amount is the broodstock cost basis reclassified to shrimp held for sale as those costs are applicable expenditures and charges directly and indirectly incurred in bringing shrimp inventory to its existing condition and location as noted in FASB ASC 330-10-30. Although, these animals will eventually come to end of life, their costs are considered part of the necessary costs to birthing and raising shrimp held for sale.

Just prior to harvest, the Company segregates and retains selected premium shrimp to become broodstock for the following shrimp harvest cycle. Upon identification and segregation, the selected animals are transferred from outdoor ponds to specialized indoor tanks. These tanks are highly regulated with respect to temperature, lighting and salinity levels. Costs allocated to broodstock animals at June 30, 2025 and June 30, 2024 totaled $54,869 and $90,549, respectively.

The number of broodstock was maintained at 4,415 in the year ended December 31, 2024 to the current reporting period of June 30, 2025.

Total inventory is as follows at:

---

| | | | |
|:---|:---|:---|:---|
|  | 2025 | 2024 | 2023 |
| Held for Sale |  |  |  |
| &nbsp;&nbsp;&nbsp;Shrimp | $– | $118259 | $– |
| &nbsp;&nbsp;&nbsp;Broodstock | 247540 | – | – |
| &nbsp;&nbsp;&nbsp;Total Held for Sale | 247540 | 118259 |  |
| Broodstock - Restocking | 54869 | 90549 | 161560 |
| Total inventory | $302409 | $208808 | $161560 |

---

NOTE 5 – PROPERTY AND EQUIPMENT

As of June 30, 2025, and June 30, 2024, the Company had the following property and equipment:

---

| | | |
|:---|:---|:---|
|  | June 30,<br>2025 | June 30,<br>2024 |
| Autos and trucks | $9179 | $66845 |
| Building and improvements | 668289 | 668289 |
| Farm equipment | 348949 | 440598 |
| Other equipment | 85332 | 646066 |
|  | 1111750 | 1821798 |
| Less: accumulated depreciation | (460812) | (545522) |
|  | 650938 | 1276276 |
| Land | 126243 | 6126242 |
| &nbsp;&nbsp;&nbsp;Net property and equipment | $777180 | $7402518 |

---

NOTE 6 –NOTES PAYABLE

Notes payable as of June 30, 2025 and June 30, 2024, consisted of the following:

---

| | | |
|:---|:---|:---|
|  | June 30,<br>2025 | June 30,<br>2024 |
| Note to an entity by the former owner of farm property, interest at 6.00%, due in monthly installments of $38,687 including interest, secured by real property, due in 2039 | $– | $4707902 |
| Promissory Note to 1800 Diagonal, a commercial lender, with a one-time interest of 13%, due in four installments beginning August 30, 2024, and a due in total by November 30, 2024, Original Discount 18,600 | 52253 | 93000 |
| Promissory Note to 1800 Diagonal, a commercial lender, with a one-time interest of 13%, due in four installments beginning August 30, 2024, and a due in total by November 30, 2024, Original Discount 18,600 | 67400 |  |
| Secured Note to Arcadia Funding, LLC , a commercial Lender, accrued fixed interest at the rate of $12,500/ month, secured by real property, due December 16, 2024 | 350000 |  |
| Note to a bank, interest at 3.75%, due in monthly installments of $719.02 including interest, secured by real property, due in 2050 | 146875 | 148404 |
|  | 616528 | 4949306 |
| Less Current Portion | (673722) | (562063) |
| Net Long-Term Debt | $(57194) | $4387243 |

---

The estimated notes payable maturities as of June 30, 2025 are as follows:

---

| | |
|:---|:---|
| 31-Dec-24 | $673722 |
| 31-Dec-25 |  |
| 31-Dec-26 |  |
| 30-Dec-27 |  |
| 31-Dec-28 |  |
| Thereafter | – |
| **Total notes payable** | $673722 |

---

In February 2024, the Company signed an unsecured promissory note with a lender for $111,600, bearing one-time interest at the rate of 13%, and maturing on four dates beginning on August 2024 and ending on November 2024. The proceeds of this note were issued with an original issue discount of $18,600, yielding net proceeds of $93,000. Upon full maturity, the Company will have paid a total of $126,108 of principal and interest on this note.

In May 2024, the Company signed a Secured Promissory Note with a lender for $350,000 bearing fixed interest at the rate of $12,500 per month with maturity date December 2024. The Secured Promissory Note requires monthly interest payments only commencing in June 2024. Principal amount along any accrued but unpaid interest should be paid at maturity date. The note is secured by property owned by the Company and trustee by Travis L. Bence or John R. Bailey.

On December 13, 2024, due to a note holder recording a deed in lieu foreclosure, on December 2nd, 2024, TAA filed for Chapter 11 bankruptcy protection under the United States Bankruptcy Code, in the United States Bankruptcy Court for the Southern District of Texas (Case # 24-10217). TAA voluntarily filed for Chapter 11 Bankruptcy to protect the assets of the company (shrimp broodstock and key property, plant, and equipment) due to threats being made by the former farm note holder (Kings Aqua Farm LLC) in which TAA operated on. On December 2, 2024, Kings Aqua Farm LLC filed a Deed in Lieu ("DIL") of Foreclosure due to non-payment by Trans American Aquaculture. The land was conveyed back to Kings Aqua Farm because of the DIL filing and as such the total debt was extinguished. Over the next two weeks, various threats were made by Kings Aqua Farm on the assets of TAA, which are paramount to the survival and future of the company. To protect those key assets and any future business, TAA elected to file a voluntary Chapter 11 Bankruptcy.

The bankruptcy plan is currently being finalized between TAA management, its board of directors, and legal counsel. The plan confirmation hearing is scheduled for August 18, 2025, at which time, we will present the re-organization plan for the company.

In August 2024, the Company signed an unsecured promissory note with a lender for $82,800 bearing one-time interest at the rate of 13%, and maturing on four dates beginning in February 2025 and ending in May 2025. The proceeds of this note were issued with an original issue discount of $13,800 and loan cost $6,000, yielding net proceeds of $63,000. Upon full maturity, the Company will have paid a total of $93,564 of principal and interest on this note.

NOTE 7 – RELATED PARTY NOTES PAYABLE

As of June 30, 2025, shareholders have loaned the Company approximately $1,646,636 in notes which accrue interest ranging from 12% and 18% per annual period. Maturities between April 1, 2024, and July 1, 2024. Accrued interest related to these notes totaled $835,905 and $414,624 as of June 30, 2025, and June 30, 2024, respectively.

NOTE 8 – INCOME TAX

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards.

Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be covered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. An allowance has been recorded as of June 30, 2025 due to uncertainty of the realization of deferred tax asset in future periods.

Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted by the end of the reporting period, and any adjustment to tax payable in respect of previous years.

In accordance with FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes, included in ASC Topic 740, Income Taxes, the Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. There were no uncertain tax positions that required recognition by the Company. As of the date of these consolidated financial statements, the Company's federal and various state tax returns will generally remain open for the last three years.

The Company's provision for income taxes attributable to income before income taxes for the periods ended June 30, 2025 and June 30, 2024, consisted of the following:

---

| | | |
|:---|:---|:---|
|  | June 30,<br>2025 | June 30,<br>2024 |
| Deferred tax assets related to: |  |  |
| &nbsp;&nbsp;&nbsp;NOL Carryover | $589868 | $403605 |
| Deferred tax liability related to: |  |  |
| &nbsp;&nbsp;&nbsp;Property and equipment | (18050) | (8715) |
| **Deferred tax assets, gross** | 571818 | 394890 |
| Less: allowance | (394890) | (394890) |
| Net deferred tax asset (liability) | $176928 | $– |
| Current expense |  |  |
| &nbsp;&nbsp;&nbsp;Federal | $– | $– |
| &nbsp;&nbsp;&nbsp;State | – | – |
|  | $– | $– |
| Deferred income tax expense (benefit) | $– | $26937 |

---

NOTE 9 – EQUITY FINANCING AND SECURITIES PURCHASE AGREEMENT

Equity Financing Agreement

On January 20, 2023, the Company entered into an Equity Financing Agreement ("the EFA") and Registration Rights Agreement (the "Registration Rights Agreement") with GHS Investments, LLC, pursuant to which GHS agreed to purchase up to $10,000,000 in shares of the Company common stock, from time to time over the course of 24 months after effectiveness of a registration statement on Form S-1 of the underlying shares of the Company's common stock.

The EFA grants the Company the right, to direct GHS to purchase shares of the Company's common stock on any business day (a "Put"), provided that at least ten trading days (as defined in the EFA) have passed since the closing of the most recent Put. The purchase price of the shares of common stock contained in a Put shall be 80% of the lowest traded price of the Company common stock during the ten consecutive Trading Days preceding the date of the Put notice. In the event The Company up lists to Nasdaq or an equivalent national exchange, the purchase price will be 90%. No Put will be made in an amount less than $10,000 or greater than $500,000 and any single drawdown may not exceed 200% of the average daily trading dollar volume of the Company's common stock during the ten trading days preceding the Put. In no event is the Company entitled to make a Put or is GHS entitled to purchase and own cumulative shares greater than 4.99% of the Company's shares of common stock outstanding on such date.

The EFA will terminate upon any of the following events: when GHS has purchased an aggregate of $10,000,000 in the common stock of the Company pursuant to the EFA; or on the date that is 24 months from the date of the EFA.

Actual sales of shares of common stock to GHS under the EFA will depend on a variety of factors, including, the number of public shares the Company has available for trading on the open market (excluding closely held and restricted stock), market conditions, the trading price of the common stock, the number of shares outstanding, and the Company's determinations as to the appropriate sources of funding for the Company and its operations. The net proceeds under the EFA to the Company will depend on the frequency and prices at which the Company sells shares of stock to GHS.

The Registration Rights Agreement provides that the Company shall (i) use its best efforts to file with the SEC the Registration Statement within 60 calendar days of the date of the Registration Rights Agreement; and (ii) have the Registration Statement declared effective by the SEC within 60 calendar days after the date the Registration Statement is filed with the SEC, but in no event more than calendar 120 days after the Registration Statement is filed.

The Company will use the proceeds from the Puts for general corporate and working capital purposes and acquisitions or assets, businesses, or operations or for purposes the Board of Directors deems to be in the best interests of the Company.

On February 27, 2024, the Company put 4,615,277 shares of common stock to GHS at a purchase price of $0.00224 under the EFA for net proceeds of $2,106.

On May 29, 2024, the Company put 11,683,300 shares of common stock to GHS at the purchase price of $.0012 under EFA for net proceeds of $12,715.

On July 30, 2025, the Company entered into an Equity Financing Agreement ("the EFA") and Registration Rights Agreement (the "Registration Rights Agreement") with GHS Investments, LLC, pursuant to which GHS agreed to purchase up to $10,000,000 in shares of the Company common stock, from time to time over the course of 24 months after effectiveness of a registration statement on Form S-1 of the underlying shares of the Company's common stock.

The EFA grants the Company the right, to direct GHS to purchase shares of the Company's common stock on any business day (a "Put"), provided that at least ten trading days (as defined in the EFA) have passed since the closing of the most recent Put. The purchase price of the shares of common stock contained in a Put shall be 80% of the lowest traded price of the Company common stock during the ten consecutive Trading Days preceding the date of the Put notice. In the event The Company up lists to Nasdaq or an equivalent national exchange, the purchase price will be 90%. No Put will be made in an amount less than $5,000 or greater than $500,000 and any single drawdown may not exceed 200% of the average daily trading dollar volume of the Company's common stock during the ten trading days preceding the Put. In no event is the Company entitled to make a Put or is GHS entitled to purchase and own cumulative shares greater than 4.99% of the Company's shares of common stock outstanding on such date.

The EFA will terminate upon any of the following events: when GHS has purchased an aggregate of $10,000,000 in the common stock of the Company pursuant to the EFA; or on the date that is 24 months from the date of the EFA.

Actual sales of shares of common stock to GHS under the EFA will depend on a variety of factors, including, the number of public shares the Company has available for trading on the open market (excluding closely held and restricted stock), market conditions, the trading price of the common stock, the number of shares outstanding, and the Company's determinations as to the appropriate sources of funding for the Company and its operations. The net proceeds under the EFA to the Company will depend on the frequency and prices at which the Company sells shares of stock to GHS.

The Registration Rights Agreement provides that the Company shall (i) use its best efforts to file with the SEC the Registration Statement within 60 calendar days of the date of the Registration Rights Agreement; and (ii) have the Registration Statement declared effective by the SEC within 60 calendar days after the date the Registration Statement is filed with the SEC, but in no event more than calendar 120 days after the Registration Statement is filed.

The Company will use the proceeds from the Puts for general corporate and working capital purposes and acquisitions or assets, businesses, or operations or for purposes the Board of Directors deems to be in the best interests of the Company.

Securities Purchase Agreements

On January 20, 2023, The Company entered into a Securities Purchase Agreement with GHS (the "GHS SPA") pursuant to which 250 shares of Series D Preferred Stock for $250,000 were sold to GHS at a price per share of $1,000. In addition, pursuant to the GHS SPA, the Company issued to GHS warrants to purchase 46,296,296 shares of common stock exercisable at $0.005175 per share and terminating on January 20, 2028.

On April 18, 2023, the Company entered into an Amended Securities Purchase Agreement with GHS (the "Amended SPA") pursuant to which the Company sold to GHS 102 shares of Series D Preferred Stock for $102,000 ($1,000 for each share of Series D Preferred Stock). In addition, pursuant to the Amended SPA, the Company issued to GHS warrants to purchase 20,606,061 shares of Common Stock exercisable at $0.00391 per share and terminating on January 20, 2028.

On May 22, 2023, the Company entered into an Amended Securities Purchase Agreement with GHS (the "Amended SPA") pursuant to which the Company sold to GHS 184 shares of Series D Preferred Stock for $184,000 ($1,000 for each share of Series D Preferred Stock). In addition, pursuant to the Amended SPA, the Company issued to GHS warrants to purchase 42,666,667 shares of Common Stock exercisable at $0.00345 per share and terminating on January 20, 2028.

On July 6, 2023, the Company entered into an Amended Securities Purchase Agreement with GHS (the "Amended SPA") pursuant to which the Company sold to GHS 96 shares of Series D Preferred Stock for $96,000 ($1,000 for each share of Series D Preferred Stock). In addition, pursuant to the Amended SPA, the Company issued to GHS warrants to purchase 19,047,620 shares of Common Stock exercisable at $0.004025 per share and terminating on January 20, 2028.

On September 26, 2023, the Company entered into a Securities Purchase Agreement with GHS (the "September 2023 SPA") pursuant to which the Company agreed to sell GHS 151 shares of Series D.

Preferred Stock for $146,000 ($1,000 for each share of Series D Preferred Stock and five commitment shares). At the initial closing, GHS purchased 76 shares ($1,000 per share of Series D Preferred Stock) and within 25 calendar days from the initial closing, GHS agreed to purchase 70 shares of Series D Preferred Stock. In addition, pursuant to the September 2023 SPA, the Company issued to GHS warrants to purchase 14,901,961 shares of Common Stock exercisable at $0.003795 per share and terminating on September 26, 2028. On October 12, 2023, GHS purchased the remaining 70 shares of Series D Preferred Stock under the September 2023 SPA. In addition, pursuant to the September 2023 SPA, the Company issued to GHS warrants to purchase 14,705,883 shares of Common Stock exercisable at $0.003795 per share and terminating on October 12, 2028.

On March 28, 2025, the Company entered into a Securities Purchase Agreement with GHS (the "March 2025 SPA") pursuant to which the Company agreed to sell GHS 114 shares of Series D.

Preferred Stock for $104,000 ($1,000 for each share of Series D Preferred Stock and ten commitment shares). At the initial closing, GHS purchased 36 shares ($1,000 per share of Series D Preferred Stock). Additional Closings will be for the purchase of Preferred Shares as follows: (a) two (2) separate purchases of fifteen (15) and fifty three (53) shares of Preferred Stock for the purchase price of $15,000 and $53,000, respectively.

In addition, pursuant to the March 2025 SPA, the Company issued to GHS warrants to purchase 306,666,667 shares of Common Stock exercisable at $0.000115 per share and terminating on March 28, 2030.

On April 2, 2025, GHS purchased 15 shares of Series D Preferred Stock under the March 2025 SPA. 40,350,887 warrants were issued to GHS.

On June 18, 2025, GHS purchased 25 shares of Series D Preferred Stock under the March 2025 SPA. 67,251,462 warrants were issued to GHS.

During the quarter ended June 30<sup>,</sup> 2025, the Company recorded an adjustment related to the issuance of its Series C Preferred Stock. The adjustment reflects $283,967 classified as Preferred Series C Stock Payable, representing the value of preferred shares authorized for issuance but not yet physically issued.

On September 18, 2025, the Company entered into a Securities Purchase Agreement with GHS (the "September 2025 SPA") pursuant to which the Company agreed to sell GHS 63 shares of Series D Preferred Stock for $60,000 ($1,000 for each share of Series D Preferred Stock and ten commitment shares). At the initial closing, GHS purchased 19 shares ($1,000 per share of Series D Preferred Stock). Additional Closings will be for the purchase of Preferred Shares as follows: (a) separate purchases of forty-four (44) of Preferred Stock for the purchase price of $44,000.

In addition, pursuant to the September 2025 SPA, the Company issued to GHS warrants to purchase 71,250,000 shares of Common Stock exercisable at $0.000345 per share and terminating on September 18, 2030.

NOTE 10 – LITIGATION

From time to time the Company is involved in lawsuits against the Company involving general liability or various contractual matters. In the opinion of the Company's management, the potential claims against the Company not covered by insurance resulting from such litigation will not materially affect the financial position of the Company.

NOTE 11 - GOING CONCERN

The Company follows FASB ASU 2014-10 – Development Stage Entities because its principal operations have commenced, but there has been no significant revenue therefrom. To date, the Company's activities since inception have consisted principally of acquiring property, equipment, and other operating assets, raising capital, starting up production, recruiting and training personnel and raising capital.

The Company's ability to continue as a going concern is dependent on its ability to raise additional capital and implement its business plan as well as continuing to develop its brood stock in order to fulfill recently signed contracts. The financial statements do not include any adjustments that might be necessary if the business plan cannot be implemented or if additional capital cannot be raised, either of which could result in the Company not being able to continue as a going concern.

The Company is in the process of raising additional capital to support the completion of the developmental stage activities and ramp up ongoing full shrimp harvest cycles and establish its customer base. Therefore, the Company's activities are subject to significant risks and uncertainties, including failing to secure additional funding to operationalize the Company's current technology.

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

This Management's Discussion and Analysis of Financial Condition and Results of Operations contain certain forward-looking statements. Historical results may not indicate future performance. Our forward-looking statements reflect our current views about future events; are based on assumptions and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those contemplated by these statements. We undertake no obligation to publicly update or revise any forward-looking statements, including any changes that might result from any facts, events, or circumstances after the date hereof that may bear upon forward-looking statements. Furthermore, we cannot guarantee future results, events, levels of activity, performance, or achievements.

Critical Accounting Policies

The following discussions are based upon our financial statements and accompanying notes, which have been prepared in accordance with GAAP Financial Measures of the United States.

The preparation of these financial statements requires management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingencies. We continually evaluate the accounting policies and estimates used to prepare the financial statements. We base our estimates on historical experiences and assumptions believed to be reasonable under current facts and circumstances. Actual amounts and results could differ from these estimates made by management.

Accounting for Our Shrimp Inventory

Our inventory of shrimp is divided into shrimp held for sale and broodstock shrimp. Broodstock are shrimp that are used for breeding purposes; selected for their genetic, disease-free and size attributes they can be more valuable than shrimp held for sale. We collect broodstock from the biomass just before the harvest and segregate them from the shrimp that will be harvested and sold. Broodstock, because of their higher value, may be sold to other shrimp farmers in the United States and overseas. We also keep a number of broodstock for our own restocking purposes. So, during the year, our inventory can consist of shrimp held for sale, broodstock held for sale and broodstock used for restocking purposes.

Shrimp farming is a seasonal business. On a calendar year basis, we typically use the broodstock to breed our larvae shrimp during the first quarter so that by spring the shrimp are held in large post-larvae tanks for development. Later, in early summer, the shrimp are transferred to ponds where they complete the grow out process over the next five to nine months. This can vary if we have more than one cycle of shrimp. Grow out may begin in the second in the second quarter, with a second cycle grow out beginning in early summer. The first harvest cycle can occur in early fall with the second harvest cycle occurring in November or December. During 2023, we had one cycle and harvest occurred in early November 2023. During 2024, we did not stock, nor did we have a harvest. In 2025, we have not stocked the ponds or had a harvest. At this time, we are only maintaining the broodstock lines. We plan to refresh the lines in 4Q25, which will depend on investment funds raised.

Our shrimp inventory is valued at lower of cost or the net realizable value on a first-in, first-out basis.

The inventory at June 30, 2025 consists of live broodstock animals. Included in this amount are costs and charges directly and indirectly incurred in bringing shrimp inventory to its existing condition and location as noted in FASB ASC 330-10-30.

At June 30, 2025, the broodstock shrimp for the 2025 harvest had been identified and segregated from consumable shrimp in outdoor ponds to indoor tanks. The table below summarizes inventory at June 30, 2025 and 2024.

---

| | | |
|:---|:---|:---|
|  | June 30, <br> 2025 | June 30, <br> 2024 |
| Held for Sale |  |  |
| &nbsp;&nbsp;&nbsp;Shrimp | $– | $12234 |
| &nbsp;&nbsp;&nbsp;Broodstock | 247540 | – |
| &nbsp;&nbsp;&nbsp;Total Held for Sale | 247540 | 12234 |
| Broodstock - Restocking | 54869 | 358429 |
| Total inventory | $302409 | $370663 |

---

At June 30, 2025, approximately 4,415 animals of broodstock will be used to populate our next harvest in 2026. The cost of the broodstock was reclassified to broodstock held for restocking on a pro rata basis of cost per pound of the total biomass of shrimp held for sale. Subsequent costs will be allocated in accordance with ASC 330-10-30.

Business Overview

Founded in 2017, we are a leading aquaculture company that provides premium quality, farm-raised pacific white shrimp, 100% free of antibiotics and hormones, to the U.S. domestic seafood market. We believe we are a leading aquaculture company due to Best Aquaculture Practices ("BAP") guidelines,1 considering the rarity of the standards in the U.S. Although we are not currently in full compliance with BAP guidelines, we are working towards full compliance. At the moment, we adhere to BAP guidelines as part of our operating and production model. Grown at our 1,880-acre farm located in Rio Hondo, Texas, on the largest scale aquaculture farm in the U.S., our shrimp are meticulously raised to exceed in line with industry best practices according to BAP guidelines2 using only authentic, sustainable practices. Within our controlled facility, each harvest is responsibly raised and cultivated onsite with minimal ecological footprint, promising our customers a superior product developed from the highest standard of care.

We have and will continue to utilize superior genetic linage broodstock for cultivation of own post larvae in our onsite genetics, maturation and hatchery facilities. These facilities allow us to continually develop animals with increasing growth rates, lower mortality, and stronger disease resistance. We began formal production runs in 2018 and to date have produced almost one million lbs. of shrimp for consumption.

Recent trends in the shrimp industry, including that, according to preliminary 2023 data from the National Marine Fisheries Service, shrimp prices have dropped as much as 44% since 2022.3 Our business, prospects, revenues, profitability, and future growth are highly dependent upon the prices of and demand for shrimp. Our ability to borrow and to obtain additional capital on attractive terms is also substantially dependent upon shrimp prices. These prices have been and are likely to continue to be extremely volatile for seasonal, cyclical, and other reasons. Any substantial or extended decline in the price of shrimp will have a material adverse effect on our financing capacity and our prospects for commencing and sustaining any economic commercial production. In addition, increased availability of imported shrimp can affect our business by lowering commodity prices. This could reduce the value of inventories, held both by us and by our customers, and cause many of our customers to reduce their orders for new products until they can dispose of their higher-cost inventories.

Going Concern Uncertainty

As shown in the accompanying financial statements, during the three-months ended June 30, 2025, we reported a net loss of $204,038. As of June 30, 2025, our current liabilities exceeded its current assets by $4,350,706. As of June 30, 2025, we had $198 cash. During the year ended December 31, 2024, we reported a net loss of $2,808,894. As of December 31, 2024, our current liabilities exceeded our current assets by $3,351,602. As of December 31, 2024, we had $0 cash.

_______________

1 https://www.bapcertification.org/Downloadables/pdf/BAP%20-%20BAP%20Farm%20Standard%20-%20Issue%203.1%20-%2007-February-2023.pdf

2 https://www.bapcertification.org/Downloadables/pdf/BAP%20-%20BAP%20Farm%20Standard%20-%20Issue%203.1%20-%2007-February-2023.pdf

3 https://civileats.com/2023/06/20/cheap-imports-leave-us-shrimpers-struggling-to-compete/#:~:text=The%20U.S.%20Food%20and%20Drug,before%20entering%20the%20U.S.%20market

We will require additional funding to finance the growth of our operations and achieve our strategic objectives. These factors, as relative to capital raising activities, create doubt as to our ability to continue as a going concern. We are seeking to raise additional capital and are targeting strategic partners to accelerate the sales and marketing of our products and begin generating revenues. Our ability to continue as a going concern is dependent upon the success of future capital offerings or alternative financing arrangements, expansion of our operations and generating sales. The accompanying financial statements do not include any adjustments that might be necessary should we be unable to continue as a going concern. Management is actively pursuing additional sources of financing sufficient to generate enough cash flow to fund its operations; however, management cannot make any assurances that such financing will be secured.

Results of Operations for the Three-Months Ended June 30, 2025 and 2024

Revenues

For the three-months ended June 30, 2025, total revenues were $0 compared to $5,019 for the same period in 2024, a decrease of $5,019 or 100%. This decrease was related to the company not having shrimp for sale and only maintaining the broodstock for future genetic development and stocking.

Cost of Goods Sold and Gross Profit

For the three-months ended June 30, 2025, cost of goods sold was $0 compared to $1,771 for the same period in 2024, a decrease of $1,771 or 100%. This was the result of not producing and harvesting or selling shrimp during the current three months ended June 30, 2025.

The gross profit for the three-months ended June 30, 2025 was $0 for an operating profit of $0 compared to a gross profit margin of $3,248 for the same period in 2024.

Operating Expenses

General and administrative expenses for three-months ended June 30, 2025 decreased by $18,703, or 15%, to $108,290 from $126,993 for the three-months ended June 30, 2024. This decrease in expenses resulted from lower legal and professional fees and accrued payroll wages.

Other Income (Expense)

For the three-months ended June 30, 2025, we had interest expenses of $88,246 compared to interest expenses of $141,238 for the same period in 2024, a decrease in interest expense of $52,992. This decrease in interest expense was due primarily to reduction in interest related to the farm note.

Net Income (Loss)

As a result of the above, we reported a net loss of $204,038 for the three-months ended June 30, 2025 compared to a net loss of $330,311 for the three-months ended June 30, 2024.

Results of Operations for the Six-Months Ended June 30, 2025 and 2024

Revenues

For the six-months ended June 30, 2025, total revenues were $0 compared to $315,145 for the same period in 2024, a decrease of $315,145 or 100%. This decrease was related to the company not having shrimp for sale and only maintaining the broodstock for future genetic development and stocking.

Cost of Goods Sold and Gross Profit

For the six-months ended June 30, 2025, cost of goods sold was $0 compared to $223,299 for the same period in 2024, a decrease of $223,299 or 100%. This was the result of not producing and harvesting or selling shrimp during the current three months ended June 30, 2025.

The gross profit for the six-months ended June 30, 2025 was $0 for an operating profit of 0% compared to a gross profit margin of $91,846 for the same period in 2024.

Operating Expenses

General and administrative expenses for six-months ended June 30, 2025 decreased by $138,422, or 43%, to $182,961 from $321,383 for the six-months ended June 30, 2024. This reduction in expenses resulted from lower legal and professional fees and payroll wages.

Other Income (Expense)

For the six-months ended June 30, 2025, we had interest expenses of $127,282 compared to interest expenses of $273,520 for the same period in 2024, a decrease in interest expense of $146,238. This decrease in interest expense was due primarily to reduction in interest related to the farm note.

Net Income (Loss)

As a result of the above, we reported a net loss of $317,745 for the six-months ended June 30, 2025 compared to a net loss of $568,332 for the six-months ended June 30, 2024.

Liquidity and Capital Resources

As of June 30, 2025, we had a cash balance of $198, compared to a balance of $0 at June 30, 2024. We currently do not have sufficient cash to fund our operations for the next 12 months and we will require working capital to complete development and production, testing and marketing of our products and to pay for ongoing operating expenses. We anticipate adding management positions for corporate development and the corresponding operations of the Company, but this will not occur prior to obtaining additional capital. Currently, competitively priced loans from banks or other lending sources for lines of credit or similar short-term borrowings are not available to us. We have been able to raise working capital to fund operations through the issuances of convertible preferred stock to GHS, factoring our receivables, and borrowing funds from employees of the Company. As of June 30, 2025, our current liabilities exceeded our current assets by $4,350,706 as compared to June 30, 2024, when current liabilities exceeded current assets by $4,175,913, an increase of $174,793.

The Company is also a party to an SBA Loan through a bank in the original amount of $150,000 bearing interest at 3.75% per annum, due in 2050, yielding a monthly payment amount of $731.

Liquidity is also affected by notes to our shareholders. At June 30, 2025, shareholders have loaned the Company approximately $1,646,636 which notes accrue interest at ranging from 12.0% to 18% per annum and were due June 30, 2024. The Company extended this due date to July 1, 2024, and plans to extend it again to December 31, 2025. Current discussions with noteholders are underway and we expect the noteholders to agree to this extension.

In February 2024, the Company signed an unsecured promissory note with a lender for $111,600, bearing one-time interest at the rate of 13%, and maturing on four dates beginning on August 30, 2024 and ending on November 30, 2024. The proceeds of this note were issued with an original issue discount of $18,600, yielding net proceeds of $88,000. Upon full maturity, the Company will have paid a total of $126,108 of principal and interest on this note.

Cash Flows from Operating Activities

During the three-months ended June 30, 2025, net cash used in operating activities was $691,719, due mainly to a net loss of $204,038, an increase in accounts payable of $1,073,204 mostly of an payroll liabilities, professional services and reclassification of notes payment from related parties, and an increase of $607,881 in accrued interest. By comparison, during the three-months ended June 30, 2024, net cash used in operating activities was $389,780, due mainly to a net loss of $568,332, payroll liabilities, offset by an increase of $216,203 in accrued interest.

During the six-months ended June 30, 2025, net cash used in operating activities was $716,809, due mainly to a net loss of $317,745, an increase in accounts payable of $989,069 mostly of payroll liabilities, professional services and reclassification of notes payment from related parties. By comparison, during the six-months ended June 30, 2024, net cash used in operating activities was $389,780, due mainly to a net loss of $568,332, an decrease in accounts receivable of $30,526 due sales of consumable shrimp, offset by a decrease of $122,838 in inventory levels, combined decrease in accounts payable and accrued expense of $44,793 due to increased operations, and a $38,468 increase in accrued interest expense due mainly to falling into arrears on the note payable covering our farm property and increased interest expense on notes payable to shareholders.

Cash Flows from Investing Activities

During the three-months ended June 30, 2025, we had $10,616 net cash used in investing activities. During the three-months ended June 30, 2024, we had $0 net cash used in investing activities.

During the six-months ended June 30, 2025, we had $10,616 net cash used in investing activities. During the six-months ended June 30, 2024, we had $12,216 net cash used in investing activities.

Cash Flows from Financing Activities

During the three-months ended June 30, 2025, net cash provided by financing activities was $674,606 which was mainly comprised of proceeds from the purchase of Preferred Series D Shares of $40,000 and reclassification of related party notes payable. During the three-months ended June 30, 2024, net cash provided by financing activities was $338,672 which was mainly comprised of proceeds from notes payable of $350,000, offset by payments due related parties of $103,355.

During the six-months ended June 30, 2025, net cash provided by financing activities was $699,696 which was mainly comprised of proceeds from the purchase of Preferred Series D Shares of $73,000 reclassification of related party notes payable. During the six-months ended June 30, 2024, net cash provided by financing activities was $395,397 which was mainly comprised of proceeds from notes payable of $443,000, offset by payments due to shareholders of $70,850, and notes payable of $32,505.

Factors That May Affect Future Results

Management's Discussion and Analysis contains information based on management's beliefs and forward-looking statements that involve several risks, uncertainties, and assumptions. There can be no assurance that actual results will not differ materially from the forward-looking statements as a result of various factors, including but not limited to, our ability to obtain the equity/debt funding or borrowings necessary to produce, market and launch our products, our ability to successfully serially produce and market our products; our success establishing and maintaining production lines; the acceptance of our products by customers; our continued ability to pay operating costs; our ability to meet demand for our products; the amount and nature of competition from our competitors; the effects of technological changes on products and product demand; and our ability to successfully adapt to market forces and technological demands of our customers.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our consolidated financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity capital expenditures or capital resources.

Recent Accounting Pronouncements

We have provided a discussion of recent accounting pronouncements in NOTE 2 to the Quarterly Consolidated Financial Statements for June 30, 2025 and 2024.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

As a smaller reporting company, the Company has elected not to provide the disclosure required by this item.

**Item 4. Controls and Procedures**

Evaluation of Disclosure Controls and Procedures

We have established disclosure controls and procedures that are designed to ensure that information required to be disclosed in reports filed or submitted under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and, as such, is accumulated and communicated to our Chief Executive Officer and Chief Financial Officer, Adam Thomas who serves as our principal executive officer and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure. Mr. Thomas has evaluated the effectiveness of our disclosure controls and procedures, as defined in Rule 13a-15(e) of the Exchange Act, as of June 30, 2025. Based on his evaluation, Mr. Thomas concluded that, due to a material weakness in our internal control over financial reporting, our disclosure controls and procedures were not effective as of June 30, 2025. In light of the material weakness in internal control over financial reporting, we completed substantive procedures, including validating the completeness and accuracy of the underlying data used for accounting prior to filing this Form 10-Q.

These additional procedures have allowed us to conclude that, notwithstanding the material weakness in our internal control over financial reporting, the consolidated financial statements included in this Form 10-Q fairly present, in all material respects, our financial position, results of operations and cash flows for the periods presented in conformity with accounting principles generally accepted in the United States of America.

Changes in Internal Control Over Financial Reporting

There has been no change in the Company's internal control over financial reporting, as defined in Rules 13a-15(f) of the Exchange Act, during our quarter ended June 30, 2025, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

**PART II—OTHER INFORMATION**

**Item 1. Legal Proceedings.**

On December 13, 2024, due to a note holder recording a deed in lieu foreclosure, on December 2nd, 2024, TAA filed for Chapter 11 bankruptcy protection under the United States Bankruptcy Code, in the United States Bankruptcy Court for the Southern District of Texas (Case # 24-10217). TAA voluntarily filed for Chapter 11 Bankruptcy to protect the assets of the company (shrimp broodstock and key property, plant, and equipment) due to threats being made by the former farm note holder (Kings Aqua Farm LLC) in which TAA operated on. On December 2, 2024, Kings Aqua Farm LLC filed a Deed in Lieu ("DIL") of Foreclosure due to non-payment by Trans American Aquaculture. The land was conveyed back to Kings Aqua Farm because of the DIL filing. Over the next two weeks, various threats were made by Kings Aqua Farm on the assets of TAA, which are paramount to the survival and future of the company. To protect those key assets and any future business, TAA elected to file a voluntary Chapter 11 Bankruptcy.

The bankruptcy plan is currently being finalized between TAA management, its board of directors, and legal counsel. The plan confirmation hearing is scheduled for August 18, 2025, at which time, we will present the re-organization plan for the company.

Currently, there are no production operations being conducted at the farm. We are solely maintaining the broodstock as plans to exit bankruptcy are finalized.

From time to time, we may become involved in litigation relating to claims arising out of our operations in the normal course of business. We are not currently involved in any pending legal proceeding or litigation and, to the best of our knowledge, no governmental authority is contemplating any proceeding to which we are a party or to which any of our properties is subject, which would reasonably be likely to have a material adverse effect on our business, financial condition and operating results.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.**

On March 28, 2025, we entered into a Securities Purchase Agreement (the "SPA") with GHS Investments LLC ("GHS") pursuant to which the Company may sell to GHS up to an aggregate of 104 shares of Series D Preferred Stock for an aggregate of up to $104,000 ($1,000 for each share of Series D Preferred Stock).

In addition, pursuant to the SPA and at each closing, the Company agreed to issue to GHS warrants to purchase shares of the Company's Common Stock equal to 50% of the number of Conversion Shares issuable upon conversion of the shares of Series D Preferred Stock purchased by GHS with an exercise price of 115% of the closing bid price the trading day prior to each issuance.

On April 2, 2025, GHS purchased 15 shares of Series D Preferred Stock under the 2025 SPA. 40,350,887 warrants were issued to GHS.

On June 18, 2025, GHS purchased 25 shares of Series D Preferred Stock under the 2025 SPA. 67,251,462 warrants were issued to GHS.

The sales of Series D Preferred Stock and warrants were made in reliance on Rule 506(b) of Regulation D promulgated under the Securities Act of 1933, as amended (the "Securities Act"), and were made without general solicitation or advertising. The purchaser represented that it was an "accredited investor" with access to information about the Company sufficient to evaluate the investment and that the securities were being acquired without a view to distribution or resale in violation of the Securities Act. The securities offered have not been registered under the Securities Act and may not be offered or sold in the United States without registration or an applicable exemption from the registration requirements of the Securities Act. No sales commissions were paid in connection with the sales of these securities.

**Item 5. Other Information.**

During the quarter ended June 30, 2025, no director or officer of the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K.

**Item 6. Exhibits**

---

| | |
|:---|:---|
| SEC Ref. No. | Title of Document |
| 31.1\* | [Rule 13a-14(a) Certification by Principal Executive Officer](transamaqua_ex3101.htm) |
| 31.2\* | [Rule 13a-14(a) Certification by Principal Financial and Accounting Officer](transamaqua_ex3102.htm) |
| 32.1\*\* | [Section 1350 Certification of Principal Executive Officer and Principal Financial and Accounting Officer](transamaqua_ex3201.htm) |
| 101.INS\* | XBRL Instance Document |
| 101.SCH\* | XBRL Taxonomy Extension Schema Document |
| 101.CAL\* | XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF\* | XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB\* | XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE\* | XBRL Taxonomy Extension Presentation Linkbase Document |
| 104\* | Cover Page Interactive Data File (formatted in Inline XBRL, and included in exhibit 101). |

---

\*Filed with this Report.

\*\*Furnished with this Report.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | TRANS AMERICAN AQUACULTURE, INC. | TRANS AMERICAN AQUACULTURE, INC. |
| October 16, 2025 | By: | /s/ Adam Thomas |
|  |  | Adam Thomas |
|  |  | Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer) |

---

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER**

**PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF**

**THE SARBANES-OXLEY ACT OF 2002**

I, Adam Thomas, certify that:

1. I have reviewed this quarterly report on Form 10-Q/A of Trans American Aquaculture, Inc.

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in the Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in the Exchange Act Rules 13a – 15(f) and 15d – 15(f) for the Registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer is made known to us by others, particularly during the period in which this report is being prepared;

b. Designed such disclosure control over financial reporting, or caused such internal control over financial reporting got be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's issuer's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer's ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's issuer's internal control over financial reporting.

Date: October 16, 2025

By: *<u>/s/ Adam Thomas</u>*

Adam Thomas

Chief Executive Officer

(Principal Executive Officer)

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION OF CHIEF FINANCIAL OFFICER**

**PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF**

**THE SARBANES-OXLEY ACT OF 2002**

I, Adam Thomas, certify that:

1. I have reviewed this quarterly report on Form 10-Q/A of Trans American Aquaculture, Inc.

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in the Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in the Exchange Act Rules 13a – 15(f) and 15d – 15(f) for the Registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer is made known to us by others, particularly during the period in which this report is being prepared;

b. Designed such disclosure control over financial reporting, or caused such internal control over financial reporting got be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's issuer's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer's ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's issuer's internal control over financial reporting.

Date: October 16, 2025

By: *<u>/s/ Adam Thomas</u>*

Adam Thomas

Chief Financial Officer

(Principal Financial and Accounting Officer)

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER**

**PURSUANT TO 18 U.S.C. SECTION 1350**

In connection with the Quarterly Report of Trans American Aquaculture, Inc. (the "Company") on Form 10-Q Amendment 1 for the quarter ending June 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Adam Thomas, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

By: *<u>/s/ Adam Thomas</u>*

Adam Thomas

Chief Executive Officer and Chief Financial Officer

(Principal Executive Officer and Principal

Financial and Accounting Officer)

Date: October 16, 2025